Misuse and Abuse of DEA Schedule II-V Opioid Analgesic Drugs: Researching Strategies to Ensure Safe Use and Reduce Preventable Harm (U01)

Post Date

March 15th 2012

Application Due Date

May 9th 2012

Funding Opportunity Number

RFA-FD-12-005

CFDA Number(s)

93.103

Funding Instrument Type(s)

Cooperative Agreement

Funding Activity Categories

Consumer Protection
Food and Nutrition
Health
Information and Statistics

Number of Awards

4

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses

Funding

• Estimated Total Funding:

  $300000

• Award Range:

  $0 - $75000

Grant Description

As part of the FDA's Safe Use Initiative's mission to seek solutions to reduce preventable harm from suboptimal use (e.g., misuse and abuse) of medications, CDER is seeking to support a limited number of research projects aimed at examining interventions and strategies that can be used by prescribers to increase the safe use and reduce misuse and abuse of opioid analgesic drugs. This funding opportunity announcement (FOA), issued by the FDA, will provide resources for research to further define the knowledge, attitudes, and behaviors that lead to inappropriate use and abuse of opioid analgesics; to research and implement strategies impacting inappropriate use and abuse of these drugs; and subsequently reduce the preventable harm, morbidity and mortality caused by Schedule II-V prescription opioid analgesic drugs. Inappropriate use and abuse can include but is not limited to prescriber misprescribing or over-prescribing and patient or citizen use of a drug in a manner that is not its intended use (e.g., non-medical use), dose or schedule, or inappropriate or inadvertent mixing of multiple drugs that interact. The goal of this FOA is to increase the body of knowledge around effective strategies that can reduce misuse and abuse of prescription opioid analgesic drugs, and are applicable in a variety of settings and can be easily sustained by the people who will implement and use the strategies.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  Food and Drug Administration

• Agency Contact:

  Stephanie D. Bogan
  Grants Management Specialist

• Agency Mailing Address:

  e-mail

• Agency Email Address:

  stephanie.bogan@fda.hhs.gov

• More Information:

  Full Announcement - NIH Guide for Grants and Contracts